Guide to buying Merck-and-Company stock in Canada

Merck-and-Company is a drug manufacturers - general business based in the US. Merck-and-Company stocks (MRK) are listed on the NYSE, and all prices are listed in US Dollars.

Its last market close was $101.83, which is a decrease of 3.62% over the previous week. Merck-and-Company employs 73,000 staff and has a trailing 12-month revenue of around $64.2 billion.

Keep reading to see up-to-date Merck-and-Company stock price and performance data, along with a step-by-step guide for how to buy Merck-and-Company stock in Canada.

Merck-and-Company (MRK) stock summary

Company stock name	Merck & Company Inc
Stock ticker symbol	MRK
Exchange	NYSE
Open	$104.72
High	$105.68
Low	$101.71
Close	$101.83
Adjusted closing	$101.83
Volume The number of stocks traded during the day	14,178,308
52-week stock price range	$71.87 – $105.84
Where to buy Merck-and-Company stock	Buy on CIBC Investor's Edge

The values in this table are accurate as of the market close on November 30, 2025, and all amounts are in USD.

Can I buy Merck-and-Company stock in Canada?

Yes, you can buy Merck-and-Company stock in Canada. You simply need to open a brokerage account with an online trading platform that supports stocks on the NYSE exchange. Platforms like Interactive Brokers will allow you to directly buy Merck-and-Company stock from within Canada.

Dive deeper: Detailed guide on how to buy stocks in Canada

Our top picks for where to buy Merck-and-Company stock

Merck-and-Company stock chart (NYSE: MRK)

This chart tracks Merck-and-Company stock price performance over time.

Merck-and-Company stock price

Merck-and-Company's stock price at the last available market close was $101.83 (as of November 30, 2025). Keep in mind that Merck-and-Company's stock price can be impacted on a daily, or even hourly, basis by factors like company performance, the broader economy and investor sentiments.

Is Merck-and-Company stock a buy or sell right now?

The technical analysis gauge above shows real-time buy or sell ratings and analysis for Merck-and-Company stock based on your selected timeframe. It uses three widely followed indicators—moving averages, oscillators and pivots—but this does not represent investment advice or a guarantee of success. Finder may not concur with these signals and accepts no responsibility for the performance of your stocks.

Can I buy Merck-and-Company stock on the TSX?

No, you cannot buy Merck-and-Company stock on the TSX because Merck-and-Company stock is not listed on the TSX. Instead, Merck-and-Company stock is listed on the NYSE under the symbol "MRK."

That said, if you're wondering how to invest in Merck-and-Company stock in Canada, you still have the option to do so by opening a trading account with a Canadian brokerage that gives you access to NYSE, like Interactive Brokers.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Merck-and-Company stock dividends

Merck-and-Company dividend payout ratio: 37.92% of net profits

Recently Merck-and-Company has paid out, on average, around 37.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.34% of the current stock value.

This means that, over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 3.34% return on their shares in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $3.20 per share.

While Merck-and-Company's payout ratio might seem fairly standard, it's worth remembering that Merck-and-Company may be investing much of the rest of its net profits in future growth.

Merck-and-Company's next dividend payout is expected around January 8, 2026. To benefit, you'll need to buy Merck-and-Company stocks before December 15, 2025 (the "ex-dividend date").

Merck-and-Company stock performance metrics

Here are some common key metrics for Merck-and-Company stock that analysts often use to help gauge a stock's value—P/E ratio, PEG ratio and EBITDA.

• Merck-and-Company's P/E ratio

  Merck-and-Company's current share price divided by its per-share earnings (EPS) over the past 12 months gives a trailing price/earnings (P/E) ratio of roughly 13x. In other words, Merck-and-Company shares trade at around 13 times recent earnings.

  That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

• Merck-and-Company's PEG ratio

  Merck-and-Company's price/earnings-to-growth (PEG) ratio is calculated by dividing its P/E ratio by its earnings growth, which comes out to about 0.9826. A lower ratio can suggest a stock offers better value, while a higher ratio may suggest worse value.

  The PEG ratio provides a broader view than the P/E ratio alone, as it factors in Merck-and-Company's expected earnings growth. By accounting for growth, investors can use the PEG ratio to compare the valuations of multiple high-growth companies.

• Merck-and-Company's EBITDA

  Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortization) is $31.5 billion. EBITDA is a measure of a company's overall financial performance and is often used as a proxy for a company's profitability.

Has Merck-and-Company stock ever split?

Merck-and-Company's stocks were split on a 1048:1000 basis on June 2, 2021. So, if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company stocks, just the quantity.

However, indirectly, the new 4.6% lower stock price could have impacted the market appetite for Merck-and-Company stocks, which in turn could have impacted Merck-and-Company's stock price.

How volatile is Merck-and-Company stock?

Over the last 12 months, Merck-and-Company's stocks price has ranged from $71.87 to as high as $105.84. Merck-and-Company's beta measurement of stock volatility is 0.32. For comparison, the market () average beta is 1. This would suggest that Merck-and-Company's stocks are less volatile than average (on this exchange).

Some analysists use "beta" to gauge a stock's volatility. Beta is a popular way to measure a stocks volatility in relation to the market. Here is a breakdown of Merck-and-Company's beta stock volatility rating.

Merck & Company Inc company and revenue performance

Market Capitalization The total market value of Merck-and-Company's outstanding shares	$254.3 billion
Gross profit (TTM)	$50 billion
Operating margin (TTM)	40.80%
Profit margin	29.63%
Revenue (TTM)	$64.2 billion
Return on assets (TTM)	13.76%
Return on equity (TTM)	39.49%
Earnings per share (TTM)	$7.56
50-day moving stock price average The average share price over the last 50 days	$88.59
200-day moving stock price average The average share price over the last 200 days	$84.50

All dollar amounts in this table are in USD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on November 30, 2025.

Merck-and-Company company profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.

2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

• Common company-related questions about Merck-and-Company

  What percentage of Merck-and-Company is owned by insiders or institutions?
  Currently 0.058% of Merck-and-Company stocks are held by insiders and 80.304% by institutions.

  How many people work for Merck-and-Company?
  Latest data suggests 73,000 work at Merck-and-Company.

  When does the fiscal year end for Merck-and-Company?
  Merck-and-Company's fiscal year ends in December.

  Where is Merck-and-Company based?
  Merck-and-Company's address is: 126 East Lincoln Avenue, Rahway, NJ, United States, 07065

  What is Merck-and-Company's ISIN number?
  Merck-and-Company's international securities identification number is: US58933Y1055

  What is Merck-and-Company's CUSIP number?
  Merck-and-Company's Committee on Uniform Securities Identification Procedures number is: 589339209

Compare trading platforms to buy Merck-and-Company stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Do I have to pay tax on gains from Merck-and-Company stock sales in Canada?

Yes, you'll need to pay taxes in Canada on investment income, which includes any profit from selling Merck-and-Company stock. The CRA taxes investment income from stocks in Canada based on three main factors:

1. Investment income. Investment income includes money earned from interest, dividends or capital gains, which may affect how much you have to pay in taxes on stock sales in Canada.
2. Investor type. Your investment income will be taxed differently depending on whether you're a regular investor or a day trader (which means you buy and trade stocks on a daily basis as your primary form of income).
3. Tax bracket. The higher your tax bracket, the more you'll pay on income from stock sales. Your tax bracket depends on your gross income (minus deductions).

You can learn more about the tax implications of selling stocks in Canada here.

Frequently asked questions about Merck-and-Company stock

• Can I buy Merck-and-Company stock directly as a Canadian investor?

  Yes, Canadian investors can buy Merck-and-Company stock directly through various online brokerage platforms available in Canada. You can compare trading platform options and fees for buying Merck-and-Company stock in our table here.

• How much is Merck-and-Company stock worth?

  As of the last market close (on November 30, 2025), Merck-and-Company stock is worth $101.83 per share.

• Can Canadians buy American stocks?

  Yes, Canadians can buy American stocks through Canadian trading platforms that give access to American stock exchanges such as the NYSE and Nasdaq. The good news is that most Canadian brokerage platforms, like Questrade, Interactive Brokers, Moomoo and Wealthsimple, give access to US exchanges. Read our full guide on how to buy US stocks in Canada to learn more.

• Can I buy fractional shares of Merck-and-Company stock?

  Yes, it may be possible to buy fractional shares of Merck-and-Company stock depending on the trading platform you're signed up with. Fractional shares can allow you to invest in Merck-and-Company stock even when you can't afford its full share price. You can read our full guide to how fractional shares work to learn more.

  The table below shows trading apps in Canada that offer fractional shares:

  3 of 3 results

  Finder Score	Available Asset Types	Account Types	Stock Trading Fee	Monthly Account Fee
  Promoted Finder Score 8.8 Great Interactive Brokers	Finder Score 8.8 Great	Stocks, Bonds, Options, Index Funds, ETFs, Forex, Currencies, Futures	RRSP, TFSA, Personal, Joint	min $1.00, max 0.5%	$0	Go to site More info Compare product selection Compare	loading
  Finder Score 7.4 Great Moomoo Financial Canada	Finder Score 7.4 Great	Stocks, Options, ETFs	RRSP, TFSA, Personal, FHSA	$1.49/stock	$0	Get up to $4,600 in trading perks. T&Cs apply.	Go to site More info Compare product selection Compare	loading
  Finder Score 9.1 Excellent Questrade	Finder Score 9.1 Excellent	Stocks, Bonds, Options, Mutual Funds, Index Funds, ETFs, Forex, GICs, Precious Metals, IPOs	RRSP, RESP, RRIF, TFSA, Personal, Joint, FHSA	$0	$0	Get free contracts, no commissions and a 30 day free trial of Questrade Plus. Use offer code FREEOPTIONS. T&Cs apply.	Go to site More info Compare product selection Compare	loading

  loading

  Load More

  Showing 3 of 3 results

  Finder Score for stock trading platforms

  To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.

  Read the full methodology

Related: New to stock trading? Compare brokers and get tips for investing.

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.